News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News Pacvue Launches Pacvue Prism, Powering the Industry’s First Agentic Commerce Grid News DoubleVerify Expands DV Authentic AdVantage to Meta and TikTok, an AI-Powered Solution to Optimize Media Quality and Performance News 3D AI Studio Launches Flow: Node-Based 3D Workflows That Run in the Browser With No GPU or Setup News Shangri-La Group Debuts ‘Dragonbeat’ with Resounding Success, Cross-Industry Collaborations with Local Creators in Art, Fashion, Gastronomy and Music News EE Power Asia 2026 to Spotlight Technologies Driving the Next Era of Electrification News SmallBizSEO Expands SEO Services to Help Local Businesses Increase Visibility Across Google and AI-Powered Search Platforms
